[Federal Register: February 7, 2007 (Volume 72, Number 25)]
[Notices]
[Page 5689]
[DOCID:fr07fe07-61]

-----------------------------------------------------------------------

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. CP07-70-000]

Southern Natural Gas Company; Notice of Application

February 1, 2007.
    Take notice that Southern Natural Gas Company (Southern), Post
Office Box 2563, Birmingham, Alabama 35202-2563, filed in Docket No.
CP07-70-000 on January 26, 2005, an application pursuant to section
7(b) of the Natural Gas Act (NGA), to abandon, by removal, six
compressor engines at its Toca Compressor Station in St. Bernard
Parish, Louisiana (Toca Engines), all as more fully set forth in the
application which is on file with the Commission and open to public
inspection. This filing may be also viewed on the Web at http://www.ferc.gov
 using the ``eLibrary'' link. Enter the docket number

excluding the last three digits in the docket number field to access
the document. For assistance, call<PHONE_NUMBER> or TTY, (202) 208-
1659.
    To comply with the United States Environmental Protection Agency
and its national emission standards for hazardous pollutants for
stationary reciprocating internal combustion engines under the
provisions of Code 40 of the Federal Regulation Part 63 Subpart ZZZZ on
June 15, 2004, Southern proposes to abandon six essentially standby
Toca Engines. In addition, Southern submits that, by abandoning these
engines, it would avoid approximately $368,000 per year in maintenance
expenses and would also avoid approximately $3,000,000 to bring the
engines up to code. Furthermore, Southern states that it is capable of
meeting the existing gas supplies in the area without the Toca Engines.
    Pursuant to Section 157.9 of the Commission's rules, 18 CFR 157.9,
within 90 days of this Notice the Commission staff will either:
Complete its environmental assessment (EA) and place it into the
Commission's public record (eLibrary) for this proceeding; or issue a
Notice of Schedule for Environmental Review. If a Notice of Schedule
for Environmental Review is issued, it will indicate, among other
milestones, the anticipated date for the Commission staff's issuance of
the final environmental impact statement (FEIS) or EA for this
proposal. The filing of the EA in the Commission's public record for
this proceeding or the issuance of a Notice of Schedule for
Environmental Review will serve to notify federal and state agencies of
the timing for the completion of all necessary reviews, and the
subsequent need to complete all Federal authorizations within 90 days
of the date of issuance of the Commission staff's FEIS or EA.
    Any questions regarding this application should be directed to
Patrick B. Pope, Vice President and General Counsel, Southern Natural
Gas Company, Post Office Box 2563, Birmingham, Alabama 35202-2563 at
(205) 325-77126 (telephone), or Patricia S. Francis, Senior Counsel,
Southern Natural Gas Company, Post Office Box 2563, Birmingham, Alabama
35202-2563 at<PHONE_NUMBER>.
    There are two ways to become involved in the Commission's review of
this project. First, any person wishing to obtain legal status by
becoming a party to the proceedings for this project should, on or
before the comment date stated below, file with the Federal Energy
Regulatory Commission, 888 First Street, NE., Washington, DC 20426, a
motion to intervene in accordance with the requirements of the
Commission's Rules of Practice and Procedure (18 CFR 385.214 or
385.211) and the Regulations under the NGA (18 CFR 157.10). A person
obtaining party status will be placed on the service list maintained by
the Secretary of the Commission and will receive copies of all
documents filed by the applicant and by all other parties. A party must
submit 14 copies of filings made with the Commission and must mail a
copy to the applicant and to every other party in the proceeding. Only
parties to the proceeding can ask for court review of Commission orders
in the proceeding.
    However, a person does not have to intervene in order to have
comments considered. The second way to participate is by filing with
the Secretary of the Commission, as soon as possible, an original and
two copies of comments in support of or in opposition to this project.
The Commission will consider these comments in determining the
appropriate action to be taken, but the filing of a comment alone will
not serve to make the filer a party to the proceeding. The Commission's
rules require that persons filing comments in opposition to the project
provide copies of their protests only to the party or parties directly
involved in the protest.
    Persons who wish to comment only on the environmental review of
this project should submit an original and two copies of their comments
to the Secretary of the Commission. Environmental commenters will be
placed on the Commission's environmental mailing list, will receive
copies of the environmental documents, and will be notified of meetings
associated with the Commission's environmental review process.
Environmental commenters will not be required to serve copies of filed
documents on all other parties. However, the non-party commenters will
not receive copies of all documents filed by other parties or issued by
the Commission (except for the mailing of environmental documents
issued by the Commission) and will not have the right to seek court
review of the Commission's final order.
    Comments, protests and interventions may be filed electronically
via the Internet in lieu of paper. See, 18 CFR 385.2001(a)(1)(iii) and
the instructions on the Commission's Web site under the ``e-Filing''
link.
    Comment Date: February 22, 2007.

Magalie R. Salas,
Secretary.
[FR Doc. E7-2027 Filed 2-6-07; 8:45 am]

BILLING CODE 6717-01-P


[Federal Register Volume 79, Number 42 (Tuesday, March 4, 2014)]
[Rules and Regulations]
[Pages 12054-12055]
[FR Doc No: 2014-04469]

-----------------------------------------------------------------------

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

14 CFR Part 71

[Docket No. FAA-2013-0594; Airspace Docket No. 13-ASW-14]

Amendment of Class E Airspace; Burnet, TX

AGENCY: Federal Aviation Administration (FAA), DOT.

ACTION: Final rule.

-----------------------------------------------------------------------

SUMMARY: This action amends Class E airspace at Burnet, TX.
Decommissioning of the Burnet non-directional radio beacon (NDB) at
Burnet Municipal Airport--Kate Craddock Field has made reconfiguration
necessary for standard instrument approach procedures and for the
safety and management of Instrument Flight Rule (IFR) operations at the
airport.

DATES: Effective date: 0901 UTC, May 29, 2014. The Director of the
Federal Register approves this incorporation by reference action under
1 CFR Part 51, subject to the annual revision of FAA Order 7400.9 and
publication of conforming amendments.

FOR FURTHER INFORMATION CONTACT: Scott Enander, Central Service Center,
Operations Support Group, Federal Aviation Administration, Southwest
Region, 2601 Meacham Blvd., Fort Worth, TX 76137; telephone 817-321-
7716.

SUPPLEMENTARY INFORMATION:

History

    On October 1, 2013, the FAA published in the Federal Register a
notice of proposed rulemaking (NPRM) to amend Class E airspace for the
Burnet, TX, area, creating additional controlled airspace at Burnet
Municipal Airport (78 FR 60237) Docket No. FAA-2013-0594. Interested
parties were invited to participate in this rulemaking effort by
submitting written comments on the proposal to the FAA. No comments
were received. Class E airspace designations are published in paragraph
6005 of FAA Order 7400.9X dated August 7, 2013, and effective September
15, 2013, which is incorporated by reference in 14 CFR 71.1. The Class
E airspace designations listed in this document will be published
subsequently in the Order.

The Rule

    This action amends Title 14 Code of Federal Regulations (14 CFR)
Part 71 by amending Class E airspace extending upward from 700 feet
above the surface for standard instrument approach procedures at Burnet
Municipal Airport--Kate Craddock Field, Burnet, TX. Airspace
reconfiguration is necessary due to the decommissioning of the Burnet
NDB and the cancellation of the NDB approach, thereby removing the 7.4-
mile segment southwest extending from the 6.7-mile radius of the
airport. The segments north and south of the airport remain unchanged.
Controlled airspace is necessary for the safety and management of IFR
operations at the airport.
    The FAA has determined that this regulation only involves an
established body of technical regulations for which frequent and
routine amendments are necessary to keep them operationally current.
Therefore, this regulation: (1) is not a ``significant regulatory
action'' under Executive Order 12866; (2) is not a ``significant rule''
under DOT Regulatory Policies and Procedures (44 FR 11034; February 26,
1979); and (3) does not warrant preparation of a regulatory evaluation
as the anticipated impact is so minimal. Since this is a routine matter
that only affects air traffic procedures and air navigation, it is
certified that this rule, when promulgated, does not have a significant
economic impact on a substantial number of small entities under the
criteria of the Regulatory Flexibility Act.
    The FAA's authority to issue rules regarding aviation safety is
found in Title 49 of the U.S. Code. Subtitle 1, Section 106, describes
the authority of the FAA Administrator. Subtitle VII, Aviation
Programs, describes in more detail the scope of the agency's authority.
This rulemaking is promulgated under the authority described in
Subtitle VII, Part A, Subpart I, Section 40103. Under that section, the
FAA is charged with prescribing regulations to assign the use of
airspace necessary to ensure the safety of aircraft and the efficient
use of airspace. This regulation is within the scope of that authority
as it amends controlled airspace in the Burnet, TX, area.

Environmental Review

    The FAA has determined that this action qualifies for categorical
exclusion under the National Environmental Policy Act in accordance
with FAA Order 1050.1E, ``Environmental Impacts: Policies and
Procedures,'' paragraph 311a. This airspace action is not expected to
cause any potentially significant environmental impacts, and no
extraordinary circumstances exist that warrant preparation of an
environmental assessment.

List of Subjects in 14 CFR Part 71

    Airspace, Incorporation by reference, Navigation (Air).

Adoption of the Amendment

    In consideration of the foregoing, the Federal Aviation
Administration amends 14 CFR Part 71 as follows:

PART 71--DESIGNATION OF CLASS A, B, C, D, AND E AIRSPACE AREAS; AIR
TRAFFIC SERVICE ROUTES; AND REPORTING POINTS

0
1. The authority citation for 14 CFR Part 71 continues to read as
follows:

    Authority:  49 U.S.C. 106(g), 40103, 40113, 40120; E.O. 10854,
24 FR 9565, 3 CFR, 1959-1963 Comp., p. 389.

Sec.  71.1  [Amended]

0
2. The incorporation by reference in 14 CFR 71.1 of the Federal
Aviation Administration Order 7400.9X, Airspace Designations and
Reporting Points, dated August 7, 2013, and effective September 15,
2013, is amended as follows:

Paragraph 6005 Class E airspace areas extending upward from 700
feet or more above the surface.

* * * * *

ASW TX E5 Burnet, TX [Amended]

Burnet Municipal Airport--Kate Craddock Field, TX
    (Lat. 30[deg]44'20'' N., long. 98[deg]14'19'' W.)

    That airspace extending upward from 700 feet above the surface
within a 6.7-mile radius of Burnet Municipal Airport--Kate Craddock
Field, and within 2 miles each side of the 016[deg] bearing from the
airport extending from the 6.7-mile radius to 10.2 miles north of
the airport, and within 2 miles each side of the 196[deg] bearing
from the airport extending from the 6.7-mile radius to 10.3 miles
south of the airport.

    Issued in Fort Worth, Texas, on February 2, 2014.
Kent M. Wheeler,
Manager, Operations Support Group, ATO Central Service Center.
[FR Doc. 2014-04469 Filed 3-3-14; 8:45 am]
BILLING CODE 4910-13-P


[Federal Register Volume 80, Number 227 (Wednesday, November 25, 2015)]
[Notices]
[Pages 73871-73874]
[FR Doc No: 2015-30134]

-----------------------------------------------------------------------

DEPARTMENT OF TRANSPORTATION

Federal Motor Carrier Safety Administration

[Docket No. FMCSA-2015-0180]

Agency Information Collection Activities; New Information
Collection Request: 391.41 CMV Driver Medication Form

AGENCY: Federal Motor Carrier Safety Administration (FMCSA), DOT.

ACTION: Notice and request for comments.

-----------------------------------------------------------------------

SUMMARY: In accordance with the Paperwork Reduction Act of 1995, FMCSA
announces its plan to submit the Information Collection Request (ICR)

described below to the Office of Management and Budget (OMB) for its
review and approval and invites public comment on the approval of a new
ICR titled, 391.41 CMV Driver Medication Form. This ICR is voluntary
and may be utilized by medical examiners (MEs) responsible for issuing
Medical Examiner's Certificates (MECs) to commercial motor vehicle
(CMV) drivers. MEs that choose to use this ICR will do so in an effort
to communicate with treating healthcare professionals who are
responsible for prescribing certain medications, so that the ME fully
understands the reasons the medications have been prescribed. The
information obtained by the ME when utilizing this ICR will assist the
ME in determining if the driver is medically qualified under 49 CFR
391.41 and to ensure that there are no disqualifying medical conditions
or underlying medical conditions and prescribed medications that could
adversely affect their safe driving ability or cause incapacitation
constituting a risk to the public.

DATES: We must receive your comments on or before January 25, 2016.

ADDRESSES: You may submit comments identified by Federal Docket
Management System (FDMS) Docket Number FMCSA-2015-0180 using any of the
following methods:
     Federal eRulemaking Portal: http://www.regulations.gov.
Follow the online instructions for submitting comments.
     Fax: 1-202-493-2251.
     Mail: Docket Services; U.S. Department of Transportation,
1200 New Jersey Avenue SE., West Building, Ground Floor, Room W12-140,
20590-0001.
     Hand Delivery or Courier: West Building, Ground Floor,
Room W12-140, 1200 New Jersey Avenue SE., Washington, DC, between 9
a.m. and 5 p.m. e.t., Monday through Friday, except Federal holidays.
    Instructions: All submissions must include the Agency name and
docket number. For detailed instructions on submitting comments and
additional information on the exemption process, see the Public
Participation heading below. Note that all comments received will be
posted without change to http://www.regulations.gov, including any
personal information provided. Please see the Privacy Act heading
below.
    Docket: For access to the docket to read background documents or
comments received, go to http://www.regulations.gov, and follow the
online instructions for accessing the dockets, or go to the street
address listed above.
    Privacy Act: In accordance with 5 U.S.C. 553(c), DOT solicits
comments from the public to better inform its rulemaking process. DOT
posts these comments, without edit, including any personal information
the commenter provides, to www.regulations.gov, as described in the
system of records notice (DOT/ALL-14 FDMS), which can be reviewed at
www.dot.gov/privacy.
    Public Participation: The Federal eRulemaking Portal is available
24 hours each day, 365 days each year. You can obtain electronic
submission and retrieval help and guidelines under the ``help'' section
of the Federal eRulemaking Portal Web site. If you want us to notify
you that we received your comments, please include a self-addressed,
stamped envelope or postcard, or print the acknowledgement page that
appears after submitting comments online. Comments received after the
comment closing date will be included in the docket and will be
considered to the extent practicable.

FOR FURTHER INFORMATION CONTACT: Charles A. Horan III, Director, Office
of Carrier, Driver, and Vehicle, Safety Standards, U.S. Department of
Transportation, Federal Motor Carrier Safety Administration, West
Building 6th Floor, 1200 New Jersey Avenue SE., Washington, DC 20590.
Telephone:<PHONE_NUMBER>; email<EMAIL_ADDRESS>
SUPPLEMENTARY INFORMATION:

Background

    The primary mission of the Federal Motor Carrier Safety
Administration (FMCSA) is to reduce crashes, injuries, and fatalities
involving large trucks and buses. The Secretary of Transportation has
delegated to FMCSA its responsibility under 49 U.S.C. 31136 and 31502
to prescribe regulations that ensure that CMVs are operated safely. As
part of this mission, the Agency's Medical Programs Division works to
ensure that CMV drivers engaged in interstate commerce are physically
qualified and able to safely perform their work.
    Information used to determine and certify driver medical fitness
must be collected in order for our highways to be safe. FMCSA is the
Federal government agency authorized to require the collection of this
information and the authorizing regulations are located at 49 CFR 390-
399. FMCSA is required by statute to establish standards for the
physical qualifications of drivers who operate CMVs in interstate
commerce for non-excepted industries [49 U.S.C. 31136(a)(3) and
31502(b)]. The regulations discussing this collection are outlined in
the Federal Motor Carrier Safety Regulations (FMCSRs) at 49 CFR 390-
399. FMCSRs at 49 CFR 391.41 set forth the physical qualification
standards that interstate CMV drivers who are subject to part 391 must
meet, with the exception of commercial driver's license/commercial
learner's permit (CDL/CLP) drivers transporting migrant workers (who
must meet the physical qualification standards set forth in 49 CFR
398.3). The FMCSRs covering driver physical qualification records are
found at 49 CFR 391.43, which specify that a medical examination be
performed on CMV drivers subject to part 391 who operate in interstate
commerce. The results of the examination shall be recorded in
accordance with the requirements set forth in that section.
    49 CFR 391.41(12) states that a person is physically qualified to
drive a CMV if that person does not use any drug or substance
identified in 21 CFR 1308.11 Schedule I, an amphetamine, a narcotic, or
other habit-forming drug and does not use any non-Schedule I drug or
substance that is identified in the other Schedules in 21 part 1308
except when the use is prescribed by a licensed medical practitioner,
as defined in Sec.  382.107, who is familiar with the driver's medical
history and has advised the driver that the substance will not
adversely affect the driver's ability to safely operate a CMV.
    In 2006, FMCSA's Medical Review Board (MRB) deliberated on the
topic of the use of Schedule II medications. The MRB considered
information provided in a 2006 FMCSA sponsored Evidence Report and a
subsequent Medical Expert Panel (MEP) to examine the relationship
between the licit use of a Schedule II drug and the risk for a motor
vehicle crash. In 2013, FMCSA tasked the MRB with updating the opinions
and recommendations of the 2006 Evidence Report and MEP.
    On September 10, 2013, the MRB and Motor Carrier Safety Advisory
Committee (MCSAC) met jointly to hear presentations on the licit use of
Schedule II medications and their regulation, and on U.S. Department of
Transportation drug and alcohol testing protocols. Subsequently, the
committees engaged in a discussion on the issue as it applies to CMV
drivers. On September 11, 2013, the MRB discussed the issue in greater
detail as its task to present a letter report to the Agency relating to
CMV drivers and Schedule II medication use and to develop a form for
MEs on the National Registry of Certified Medical Examiners (National
Registry) to send to treating clinicians of CMV drivers to expound on
the use of

these medications by driver applicants. On October 22, 2013, the MRB
submitted their recommendations to FMCSA. A MEP convened to provide an
updated opinion on Schedule II Opioids and Stimulants & CMV Crash Risk
and Driver Performance. The FMCSA revised the task of the MRB
instructing them to review an updated evidence report and the MEP
opinion that was furnished subsequent to its deliberations on Schedule
II Opioids and Stimulants & CMV Crash Risk and Driver Performance:
Evidence Report and Systematic Review. FMCSA directed the MRB to
consider this report's findings and confer with the MCSAC on this topic
during a joint meeting in October 2014. The MRB met in public meetings
on July 29-30, 2014, and developed Schedule II medication
recommendations. The MRB presented these recommendations to the MCSAC
in a joint public meeting on October 27, 2014, where they were
deliberated by both committees. As a result, FMCSA's MRB and MCSAC
provided joint recommendations related to the use of Schedule II
medications by CMV drivers. Because there is moderate evidence to
support the contention that the licit use of opioids increases the risk
of motor vehicle crashes and impacts indirect measures of driver
performance negatively, included was the recommendation that FMCSA
develop a standardized medication questionnaire to assist the certified
ME when reviewing prescription medications that have been disclosed
during the history and physical examination for CMV driver
certification. The two advisory groups recommended to FMCSA that the
standardized CMV driver medication questionnaire be voluntary and
include the following information and questions:
    1. Questionnaire should be titled 391.41 CMV Driver Medication
Questionnaire.
    2. Questionnaire should request the following information:
    a. Identifying name and date of birth of the CMV driver.
    b. Introductory paragraph stating purpose of the CMV Driver
Medication Report.
    c. Statements of 391.41(b)(12) (Physical Qualifications of Drivers
relating to driver use of scheduled substances) and The Driver's Role,
as found in the Medical Examination Report form found at the end of 49
CFR 391.43 (Medical Examination; Certificate of Physical Examination).
    d. Name, state of licensure, signature, address and contact
information of the prescribing healthcare provider, as well as the date
the form was completed.
    e. Name, signature, date, address and contact information of the
certified ME.
    3. Report should include the following information:
    a. 1--List all medications and dosages that you have prescribed to
the above named individual.
    b. 2--List any other medications and dosages that you are aware
have been prescribed to the above named individual by another treating
healthcare provider.
    c. 3--What medical conditions are being treated with these
medications?
    d. 4--It is my medical opinion that, considering the mental and
physical requirements of operating a CMV and with awareness of a CMV
driver's role (consistent with The Driver's Role statement on page 2 of
the form), I believe my patient: (a) has no medication side effects
from medication(s) that I prescribe that would adversely affect the
ability to operate a CMV safely; and (2) has no medical condition(s)
that I am treating with the above medication(s) that would adversely
affect the ability to operate a CMV safely.
    The public interest in, and right to have, safe highways requires
the assurance that drivers of CMVs can safely perform the increased
physical and mental demands of their duties. FMCSA's medical standards
provide this assurance by requiring drivers to be examined and
medically certified as physically and mentally qualified to drive.
    The purpose for collecting this information is to assist the ME in
determining if the driver is medically qualified under 49 CFR 391.41
and to ensure that there are no disqualifying medical conditions that
could adversely affect their safe driving ability or cause
incapacitation constituting a risk to the public. 49 CFR 391.41(12)
states that a person is physically qualified to drive a CMV if that
person does not use any drug or substance identified in 21 CFR 1308.11
Schedule I, an amphetamine, a narcotic, or other habit-forming drug and
does not use any non-Schedule I drug or substance that is identified in
the other Schedules in 21 part 1308 except when the use is prescribed
by a licensed medical practitioner, as defined in Sec.  382.107, who is
familiar with the driver's medical history and has advised the driver
that the substance will not adversely affect the driver's ability to
safely operate a CMV.
    The use of this ICR is at the discretion of the ME to facilitate
communication with treating healthcare professionals who are
responsible for prescribing certain medications so that the ME fully
understands the reasons the medications have been prescribed. This
information will assist the ME in determining whether the underlying
medical condition and the prescribed medication will impact the
driver's safe operation of a CMV. Therefore, there is no required
collection frequency.
    The 391.41 CMV Driver Medication Form will be available as a
fillable pdf or may be downloaded from the FMCSA Web site. Prescribing
healthcare providers will also be able to fax or scan and email the
report to the certified ME. Consistent with the OMB's commitment to
minimizing respondents' recordkeeping and paperwork burdens and the
increased use of secure electronic modes of communication, the Agency
anticipates that approximately 50 percent of the 391.41 CMV Driver
Medication Forms will be transmitted electronically.
    The information collected from the 391.41 CMV Driver Medication
Form, will be used by the certified ME that requested the completion of
the form and will become part of the CMV driver's record maintained by
the certified ME. Therefore, the information will not be available to
the public. The FMCSRs covering driver physical qualification records
are found at 49 CFR 391.43, which specify that a medical examination be
performed on CMV drivers subject to part 391 who operate in interstate
commerce. The results of the examination shall be recorded in
accordance with the requirements set forth in that section. MEs are
required to maintain records of the CMV driver medical examinations
they conduct.
    Title: 391.41 CMV Driver Medication Form.
    OMB Control Number: 2126-00XX.
    Type of Request: New collection.
    Respondents: Prescribing healthcare professionals.
    Estimated Number of Respondents: 1,082,200 (total number of
prescribing healthcare providers in the U.S.)
    Estimated Time per Response: 8 minutes.
    Expiration Date: N/A. This is a new ICR.
    Frequency of Response: Voluntary.
    Estimated Total Annual Burden: 144,293 hours [1,082,200 responses x
8 minutes to complete response/60 minutes = 144,293].
    Public Comments Invited: You are asked to comment on any aspect of
this information collection, including: (1) whether the proposed
collection is necessary for the performance of FMCSA's functions; (2)
the accuracy of the estimated burden; (3) ways for FMCSA to enhance the
quality, usefulness, and clarity of the collected

information; and (4) ways that the burden could be minimized without
reducing the quality of the collected information. The agency will
summarize or include your comments in the request for OMB's clearance
of this information collection.

    Issued under the authority of 49 CFR 1.87 on: Nov 6, 2015.
G. Kelly Regal,
Associate Administrator for Office of Research and Information
Technology.
[FR Doc. 2015-30134 Filed 11-24-15; 8:45 am]
BILLING CODE 4910-EX-P


[Federal Register Volume 79, Number 71 (Monday, April 14, 2014)]
[Rules and Regulations]
[Pages 20768-20769]
[FR Doc No: 2014-08275]

=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

14 CFR Part 25

[Docket No. FAA-2013-0772; Special Conditions No. 25-520-SC]

Special Conditions: Embraer S.A., Model EMB-550 Airplanes; Flight
Envelope Protection: Normal Load Factor (g) Limiting

AGENCY: Federal Aviation Administration (FAA), DOT.

ACTION: Final special conditions.

-----------------------------------------------------------------------

SUMMARY: These special conditions are issued for the Embraer S.A. Model
EMB-550 airplane. This airplane will have a novel or unusual design
feature associated with an electronic flight control system that
prevents the pilot from inadvertently or intentionally exceeding the
positive or negative airplane limit load factor. The applicable
airworthiness regulations do not contain adequate or appropriate safety
standards for this design feature. These special conditions contain the
additional safety standards that the Administrator considers necessary
to establish a level of safety equivalent to that established by the
existing airworthiness standards.

DATES: Effective Date: May 14, 2014.

FOR FURTHER INFORMATION CONTACT: Joe Jacobsen, FAA, Airplane and Flight
Crew Interface Branch, Transport Airplane Directorate, Aircraft
Certification Service, 1601 Lind Avenue SW., Renton, Washington 98057-
3356; telephone<PHONE_NUMBER>; facsimile<PHONE_NUMBER>.

SUPPLEMENTARY INFORMATION:

Background

    On May 14, 2009, Embraer S.A. applied for a type certificate for
its new Model EMB-550 airplane. The Model EMB-550 airplane is the first
of a new family of jet airplanes designed for corporate flight,
fractional, charter, and private owner operations. The airplane has a
conventional configuration with low wing and T-tail empennage. The
primary structure is metal with composite empennage and control
surfaces. The Model EMB-550 airplane is designed for 8 passengers, with
a maximum of 12 passengers. It is equipped with two Honeywell HTF7500-E
medium bypass ratio turbofan engines mounted on aft fuselage pylons.
Each engine produces approximately 6,540 pounds of thrust for normal
takeoff. The primary flight controls consist of hydraulically powered
fly-by-wire elevators, ailerons, and rudders controlled by the pilot or
copilot sidestick.
    The design of the electronic flight control system for the Model
EMB-550 airplane incorporates normal load factor limiting on a full
time basis that prevents the flight crew from inadvertently or
intentionally exceeding the positive or negative airplane limit load
factor. This feature is considered novel and unusual in that the
current regulations do not provide standards for maneuverability and
controllability evaluations for such systems.

Type Certification Basis

    Under the provisions of Title 14, Federal Code of Regulations (14
CFR) 21.17, Embraer S.A. must show that the Model EMB-550 airplane
meets the applicable provisions of part 25, as amended by Amendments
25-1 through 25-127 thereto.
    If the Administrator finds that the applicable airworthiness
regulations (i.e., 14 CFR part 25) do not contain adequate or
appropriate safety standards for the Model EMB-550 airplane because of
a novel or unusual design feature, special conditions are prescribed
under the provisions of Sec.  21.16.
    Special conditions are initially applicable to the model for which
they are issued. Should the type certificate for that model be amended
later to include any other model that incorporates the same or similar
novel or unusual design feature, the special conditions would also
apply to the other model under Sec.  21.101.
    In addition to the applicable airworthiness regulations and special
conditions, the Model EMB-550 airplane must comply with the fuel vent
and exhaust emission requirements of 14 CFR part 34 and the noise
certification requirements of 14 CFR part 36, and the FAA must issue a
finding of regulatory adequacy under Sec.  611 of Public Law 92-574,
the ``Noise Control Act of 1972.''
    The FAA issues special conditions, as defined in 14 CFR 11.19, in
accordance with Sec.  11.38, and they become part of the type-
certification basis under Sec.  21.17(a)(2).

Novel or Unusual Design Features

    The Model EMB-550 airplane will incorporate the following novel or
unusual design features: The design of the electronic flight control
system incorporates normal load factor limiting on a full-time basis
that will prevent the flight crew from inadvertently or intentionally
exceeding the positive or negative airplane limit load factor. This
feature is considered novel because the current regulations do not
provide standards for maneuverability and controllability evaluations
for such systems. Therefore, special conditions are needed to ensure
adequate maneuverability and controllability when using this design
feature.

Discussion

    Title 14, Code of Federal Regulations, part 25 sections do not
specify requirements or policy for demonstrating maneuver control that
impose any handling qualities requirements beyond the design limit
structural loads. Nevertheless, some pilots have become accustomed to
the availability of this excess maneuver capacity in case of extreme
emergency such as upset recoveries or collision avoidance.
    As with previous fly-by-wire airplanes, the FAA has no regulatory
or safety reason to prohibit a design for an electronic flight control
system with load factor limiting. It is possible that pilots accustomed
to this feature feel more freedom in commanding full-stick displacement
maneuvers because of the following:
     Knowledge that the limit system will protect the
structure,
     Low stick force/displacement gradients,
     Smooth transition from pilot elevator control to limit
control.
    These special conditions will ensure adequate maneuverability and
controllability when using this design feature.

Discussion of Comments

    Notice of proposed special conditions No. 25-13-05-SC for Embraer
S.A. Model EMB-550 airplanes was published in the Federal Register on
October 25, 2013 (78 FR 63902). No comments were received, and the
special conditions are adopted as proposed.

Applicability

    As discussed above, these special conditions are applicable to the
Model EMB-550 airplane. Should Embraer S.A. apply at a later date for a
change to the type certificate to include another model incorporating
the same novel or unusual design feature, the special conditions would
apply to that model as well.

Conclusion

    This action affects only certain novel or unusual design features
on one model of airplanes. It is not a rule of general applicability.

List of Subjects in 14 CFR Part 25

    Aircraft, Aviation safety, Reporting and recordkeeping
requirements.

0
The authority citation for these special conditions is as follows:

    Authority: 49 U.S.C. 106(g), 40113, 44701, 44702, 44704.

The Special Conditions

    Accordingly, pursuant to the authority delegated to me by the
Administrator, the following special conditions are issued as part of
the type certification basis for Embraer S.A. Model EMB-550 airplanes.
    1. Flight Envelope Protection: Normal Load Factor (g) Limiting.
    To meet the intent of adequate maneuverability and controllability
required by Sec.  25.143(a), and in addition to the requirements of
Sec.  25.143(a) and in the absence of other limiting factors, the
following special conditions are issued based on Sec.  25.333(b):
    (a) The positive limiting load factor must not be less than:
    (1) 2.5g for the normal state of the electronic flight control
system with the high lift devices retracted.
    (2) 2.0g for the normal state of the electronic flight control
system with the high lift devices extended.
    (b) The negative limiting load factor must be equal to or more
negative than:
    (1) Minus 1.0g for the normal state of the electronic flight
control system with the high lift devices retracted.
    (2) 0.0g for the normal state of the electronic flight control
system with high lift devices extended.
    (c) Maximum reachable positive load factor wings level may be
limited by the characteristics of the electronic flight control system
or flight envelope protections (other than load factor protection)
provided that:
    (1) The required values are readily achievable in turns, and
    (2) That wings level pitch up is satisfactory.
    (d) Maximum achievable negative load factor may be limited by the
characteristics of the electronic flight control system or flight
envelope protections (other than load factor protection) provided that:
    (1) Pitch down responsiveness is satisfactory, and
    (2) From level flight, 0g is readily achievable, or alternatively,
a satisfactory trajectory change is readily achievable at operational
speeds. For the FAA to consider a trajectory change as satisfactory,
the applicant should propose and justify a pitch rate that provides
sufficient maneuvering capability in the most critical scenarios.
    (e) Compliance demonstration with the above requirements may be
performed without ice accretion on the airframe.
    (f) These special conditions do not impose an upper bound for the
normal load factor limit, nor does it require that the limiter exist.
If the limit is set at a value beyond the structural design limit
maneuvering load factor n of Sec. Sec.  25.333(b), 25.337(b),
25.337(c), there should be a very obvious positive tactile feel built
into the controller so that it serves as a deterrent to inadvertently
exceeding the structural limit.

    Issued in Renton, Washington, on April 8, 2014.
John P. Piccola,
Acting Manager, Transport Airplane Directorate, Aircraft Certification
Service.
[FR Doc. 2014-08275 Filed 4-11-14; 8:45 am]
BILLING CODE 4910-13-P


[Federal Register Volume 87, Number 218 (Monday, November 14, 2022)]
[Notices]
[Pages 68179-68180]
[FR Doc No: 2022-24707]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2021-D-0997]

Referencing the Definition of ``Device'' in the Federal Food,
Drug, and Cosmetic Act in Guidance, Regulatory Documents,
Communications, and Other Public Documents; Guidance for Industry and
Food and Drug Administration Staff; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of availability.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA, Agency, or we) is
announcing the availability of a final guidance entitled ``Referencing
the Definition of `Device' in the Federal Food, Drug, and Cosmetic Act
in Guidance, Regulatory Documents, Communications, and Other Public
Documents.'' FDA is issuing this guidance to promote clarity regarding
references to the terms ``device'' and ``counterfeit device'' in
guidance, regulatory documents, communications, and other public
documents.

DATES: The announcement of the guidance is published in the Federal
Register on November 14, 2022.

ADDRESSES: You may submit either electronic or written comments on
Agency guidances at any time as follows:

Electronic Submissions

    Submit electronic comments in the following way:
     Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments. Comments submitted
electronically, including attachments, to https://www.regulations.gov
will be posted to the docket unchanged. Because your comment will be
made public, you are solely responsible for ensuring that your comment
does not include any confidential information that you or a third party
may not wish to be posted, such as medical information, your or anyone
else's Social Security number, or confidential business information,
such as a manufacturing process. Please note that if you include your
name, contact information, or other information that identifies you in
the body of your comments, that information will be posted on https://www.regulations.gov.
     If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').

Written/Paper Submissions

    Submit written/paper submissions as follows:
     Mail/Hand Delivery/Courier (for written/paper
submissions): Dockets Management Staff (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
     For written/paper comments submitted to the Dockets
Management Staff, FDA will post your comment, as well as any
attachments, except for information submitted, marked and identified,
as confidential, if submitted as detailed in ``Instructions.''
    Instructions: All submissions received must include the Docket No.
FDA-2021-D-0997 for ``Referencing the Definition of `Device' in the
Federal Food, Drug, and Cosmetic Act in Guidance, Regulatory Documents,
Communications, and Other Public

Documents.'' Received comments will be placed in the docket and, except
for those submitted as ``Confidential Submissions,'' publicly viewable
at https://www.regulations.gov or at the Dockets Management Staff
between 9 a.m. and 4 p.m., Monday through Friday,<PHONE_NUMBER>.
     Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will
review this copy, including the claimed confidential information, in
its consideration of comments. The second copy, which will have the
claimed confidential information redacted/blacked out, will be
available for public viewing and posted on https://www.regulations.gov.
Submit both copies to the Dockets Management Staff. If you do not wish
your name and contact information to be made publicly available, you
can provide this information on the cover sheet and not in the body of
your comments and you must identify this information as
``confidential.'' Any information marked as ``confidential'' will not
be disclosed except in accordance with 21 CFR 10.20 and other
applicable disclosure law. For more information about FDA's posting of
comments to public dockets, see 80 FR 56469, September 18, 2015, or
access the information at: https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
    Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in
the heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane,
Rm. 1061, Rockville, MD 20852,<PHONE_NUMBER>.
    You may submit comments on any guidance at any time (see 21 CFR
10.115(g)(5)).
    An electronic copy of the guidance document is available for
download from the internet. See the SUPPLEMENTARY INFORMATION section
for information on electronic access to the guidance. Submit written
requests for a single hard copy of the guidance document entitled
``Referencing the Definition of `Device' in the Federal Food, Drug, and
Cosmetic Act in Guidance, Regulatory Documents, Communications, and
Other Public Documents'' to the Office of Policy, Center for Devices
and Radiological Health, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 66, Rm. 5431, Silver Spring, MD 20993-0002. Send
one self-addressed adhesive label to assist that office in processing
your request.

FOR FURTHER INFORMATION CONTACT: Eli Tomar, Center for Devices and
Radiological Health, Food and Drug Administration, 10903 New Hampshire
Ave., Bldg. 66, Rm. 5462, Silver Spring, MD 20993-0002,<PHONE_NUMBER>;
or Stephen Ripley, Center for Biologics Evaluation and Research, Food
and Drug Administration, 10903 New Hampshire Ave., Bldg. 71, Rm. 7301,
Silver Spring, MD 20993,<PHONE_NUMBER>.

SUPPLEMENTARY INFORMATION:

I. Background

    For many years, the definition of ``device'' has been codified at
section 201(h) of the Federal Food, Drug, and Cosmetic Act (FD&C Act)
(21 U.S.C. 321(h)). As a result of the enactment of the Safeguarding
Therapeutics Act (Pub. L. 116-304), the definition of ``device'' was
redesignated as subsection (h)(1) and a new definition of ``counterfeit
device'' was codified at subsection (h)(2) of section 201 of the FD&C
Act.
    FDA is issuing this final guidance to clarify how the Agency
intends to interpret existing references to section 201(h) of the FD&C
Act and how we intend to reference the definitions of ``device'' and
``counterfeit device'' going forward. This guidance is intended to
provide clarity on references to the terms ``device'' and ``counterfeit
device''--as well as references to section 201(h) of the FD&C Act--in
guidance, regulatory documents, and other communications and documents
for FDA staff, industry, and other stakeholders. To minimize the
potential for miscommunication, FDA also encourage stakeholders, to the
extent practicable, to align with the conventions described in the
guidance.
    A notice of availability of the draft guidance appeared in the
Federal Register of December 16, 2021 (86 FR 71507). FDA considered
comments received and revised the guidance to improve clarity,
including adding examples of how the policy in the guidance should be
applied.
    This guidance is being issued consistent with FDA's good guidance
practices regulation (21 CFR 10.115). The guidance represents the
current thinking of FDA on ``Referencing the Definition of `Device' in
the Federal Food, Drug, and Cosmetic Act in Guidance, Regulatory
Documents, Communications, and Other Public Documents.'' It does not
establish any rights for any person and is not binding on FDA or the
public. You can use an alternative approach if it satisfies the
requirements of the applicable statutes and regulations.

II. Electronic Access

    Persons interested in obtaining a copy of the guidance may do so by
downloading an electronic copy from the internet. A search capability
for all Center for Devices and Radiological Health guidance documents
is available at https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/guidance-documents-medical-devices-and-radiation-emitting-products. This guidance document is also
available at https://www.regulations.gov, https://www.fda.gov/regulatory-information/search-fda-guidance-documents, or https://www.fda.gov/vaccines-blood-biologics/guidance-compliance-regulatory-information-biologics. Persons unable to download an electronic copy of
``Referencing the Definition of `Device' in the Federal Food, Drug, and
Cosmetic Act in Guidance, Regulatory Documents, Communications, and
Other Public Documents'' may send an email request to [email protected] to receive an electronic copy of the document.
Please use the document number 21008 and complete title to identify the
guidance you are requesting.

III. Paperwork Reduction Act of 1995

    FDA concludes that this guidance contains no collection of
information. Therefore, clearance by the Office of Management and
Budget under the Paperwork Reduction Act of 1995 is not required.

    Dated: November 8, 2022.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2022-24707 Filed 11-10-22; 8:45 am]
BILLING CODE 4164-01-P


[Federal Register: July 11, 2008 (Volume 73, Number 134)]
[Notices]
[Page 39969-39970]
[DOCID:fr11jy08-52]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2008-D-0137] (formerly Docket No. 2000D-1383)

Guidance for Industry and Food and Drug Administration Staff;
Surveillance and Detention Without Physical Examination of Condoms;
Availability

AGENCY:  Food and Drug Administration, HHS.

ACTION:  Notice.

-----------------------------------------------------------------------

SUMMARY:  The Food and Drug Administration (FDA) is announcing the
availability of the guidance entitled ``Surveillance and Detention
Without Physical Examination of Condoms.'' This guidance document
provides information to FDA staff and industry about FDA's strategy for
addressing further imports of condoms from manufacturers/shippers whose
condoms have failed to meet FDA's minimum acceptable quality criteria.
The guidance and the strategy are intended to help assure that condoms
imported to the United States do not have defects that could compromise
their effectiveness and present a health hazard to consumers who rely
on condoms for protection from sexually transmitted diseases as well as
for contraception.

DATES:  Submit written or electronic comments on this guidance at any
time. General comments on agency guidance documents are welcome at any
time.

ADDRESSES:  Submit written requests for single copies of the guidance
document entitled ``Surveillance and Detention Without Physical
Examination of Condoms'' to the Division of Small Manufacturers,
International, and Consumer Assistance (HFZ-220), Center for Devices
and Radiological Health, Food and Drug Administration, 1350 Piccard
Dr., Rockville, MD 20850. Send one self-addressed adhesive label to
assist that office in processing your request, or fax your request to
240-276-3151. See the SUPPLEMENTARY INFORMATION section for information
on electronic access to the guidance.
    Submit written comments concerning this guidance to the Division of
Dockets Management (HFA-305), Food and Drug Administration, 5630
Fishers Lane, rm. 1061, Rockville, MD 20852. Submit electronic comments
to http://www.regulations.gov. Identify comments with the docket number
found in brackets in the heading of this document.

FOR FURTHER INFORMATION CONTACT:  J. Michael Kuchinski, Center for
Devices and Radiological Health (HFZ-332), Food and Drug
Administration, 2094 Gaither Rd., Rockville, MD 20850,<PHONE_NUMBER>.

SUPPLEMENTARY INFORMATION:

I. Background

    Consumers use condoms as a barrier to reduce the risk of catching
or spreading sexually transmitted diseases and to reduce the risk of
unintended pregnancy. Defective condoms present a potentially
significant hazard to health for these users.
    FDA's Center for Devices and Radiological Health (CDRH) is aware
that some foreign manufacturers and shippers of condoms repeatedly
attempt to import condoms that fail water leak testing, indicating a
level of defects that does not satisfy the acceptable quality criteria
described in Compliance Policy Guide 7124.21. To address the issue of
firms that repeatedly offer nonconforming condoms for import to the
United States, FDA has devised a risk-based tiered process for placing
condoms from identified manufacturers/shippers on an import alert, for
releasing individual shipments, and for removing condoms from
identified manufacturers/shippers from the import alert and consequent
potential detention without physical examination. The process involves
three levels of import surveillance and detention that may be applied
over a 24-month import surveillance cycle.
    This final guidance document supersedes the draft guidance entitled
``Surveillance and Detention Without Physical Examination of Condoms,''
which was announced in the Federal Register on August 14, 2000 (65 FR
49585). The comment period closed on November 13, 2000.
    We received a small number of comments, and FDA has made some
changes to the final guidance document based on these comments. One
comment indicated that the risk of detention is greater for high-volume
manufacturers because they have many shipments and many FDA analyses in
a 24-month period and, therefore, a greater cumulative risk of Type 1
statistical sampling error resulting in some shipments failing analyses
even though the shipments are acceptable. After analyzing the import
data, FDA agrees that, in theory, such sampling errors are possible,
although FDA believes that such errors are unlikely to affect most
condom manufacturers because they appear to be producing condoms at a
defect rate well below the acceptance criteria of the FDA test.
Nevertheless, the revised document recognizes the opportunity for

manufacturers to present evidence to FDA in support of a
reconsideration of their listing on the import alert if they believe
for any reason that this listing is inappropriate, including as a
result of statistical sampling errors or because previous defective
shipments were found during a previously concluded import surveillance
cycle.
    Another change in the final guidance is that the 24-month
surveillance period will start when a firm is placed on Level 1 rather
than when a firm is removed from Level 1, as proposed in the draft
guidance. This change is being implemented to simplify the process and
provide a ``level playing field'' for low-volume firms that export
shipments of condoms to the United States less frequently than high-
volume firms and therefore generally take a longer time to obtain a
number of consecutive passing entries sufficient for removal from the
import alert.

II. Significance of Guidance

    This guidance is being issued consistent with FDA's good guidance
practices regulation (21 CFR 10.115). The guidance represents the
agency's current thinking on ``Surveillance and Detention Without
Physical Examination of Condoms.'' It does not create or confer any
rights for or on any person and does not operate to bind FDA or the
public. An alternative approach may be used if such approach satisfies
the requirements of the applicable statute and regulations.

III. Electronic Access

    Persons interested in obtaining a copy of the guidance may do so by
using the Internet. To receive ``Surveillance and Detention Without
Physical Examination of Condoms,'' you may either send an e-mail
request to<EMAIL_ADDRESS>to receive an electronic copy of the
document or send a fax request to<PHONE_NUMBER> to receive a hard copy.
Please use the document number 1139 to identify the guidance you are
requesting.
    CDRH maintains an entry on the Internet for easy access to
information including text, graphics, and files that may be downloaded
to a personal computer with Internet access. Updated on a regular
basis, the CDRH home page includes device safety alerts, Federal
Register reprints, information on premarket submissions (including
lists of approved applications and manufacturers' addresses), small
manufacturer's assistance, information on video conferencing and
electronic submissions, Mammography Matters, and other device-oriented
information. The CDRH Web site may be accessed at http://www.fda.gov/
cdrh. A search capability for all CDRH guidance documents is available
at http://www.fda.gov/cdrh/guidance.html. Guidance documents are also
available at http://www.regulations.gov.

IV. Paperwork Reduction Act of 1995

    This guidance refers to previously approved collections of
information found in FDA regulations. These collections of information
are subject to review by the Office of Management and Budget (OMB)
under the Paperwork Reduction Act of 1995 (PRA) (44 U.S.C. 3501-3520).
The collections of information in 21 CFR part 820 have been approved
under OMB control number 0910-0073.
    The information collection recommendations included in this
document as part of the strategy for addressing further shipments of
condoms from manufacturers/shippers who repeatedly export defective
condoms to the United States do not require OMB clearance under the
PRA. These collections of information are excepted from the
requirements of the PRA under 5 CFR 1320.4(a)(2) and (c). The guidance
recommends information to be collected and submitted to FDA ``during
the conduct of an administrative action, investigation, or audit
involving the agency against specific individuals'' (5 CFR
1320.4(a)(2)) and ``after a case file or equivalent is opened with
respect to a particular party'' (5 CFR 1320.4(c)) in order for that
specific party to rebut the appearance of adulteration and consequently
obtain release of a specific shipment of condoms or removal of specific
condoms from listing on Import Alert.

V. Comments

    Interested persons may submit to the Division of Dockets Management
(see ADDRESSES) written or electronic comments regarding this document.
Submit a single copy of electronic comments or two paper copies of any
mailed comments, except that individuals may submit one paper copy.
Comments are to be identified with the docket number found in brackets
in the heading of this document. Received comments may be seen in the
Division of Dockets Management between 9 a.m. and 4 p.m., Monday
through Friday.
    Please note that on January 15, 2008, the FDA Division of Dockets
Management Web site transitioned to the Federal Dockets Management
System (FDMS). FDMS is a Government-wide, electronic docket management
system. Electronic comments or submissions will be accepted by FDA only
through FDMS at http://www.regulations.gov.

    Dated: July 1, 2008.
Jeffrey Shuren,
Associate Commissioner for Policy and Planning.
[FR Doc. E8-15765 Filed 7-10-08; 8:45 am]

BILLING CODE 4160-01-S


[Federal Register Volume 78, Number 228 (Tuesday, November 26, 2013)]
[Notices]
[Page 70549]
[FR Doc No: 2013-28345]

-----------------------------------------------------------------------

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Project No. 14539-000; Project No. 14540-000]

Lock+ Hydro Friends Fund III, LLC, Western Minnesota Municipal
Power Agency; Notice Announcing Preliminary Permit Drawing

    The Commission has received two preliminary permit applications
deemed filed on July 23, 2013 at 8:30 a.m.,\1\ for proposed projects to
be located at the U.S. Army Corps of Engineers' Melvin Price Locks and
Dam on the Mississippi River, near the City of Alton, in Madison
County, Illinois, and the City of West Alton, in St. Charles County,
Missouri. The applications were filed by Lock+ Hydro Friends Fund III,
LLC for Project No. 14539-000 and Western Minnesota Municipal Power
Agency for Project No. 14540-000.
---------------------------------------------------------------------------

    \1\ Under the Commission's Rules of Practice and Procedure, any
document received after regular business hours is considered filed
at 8:30 a.m. on the next regular business day. See 18
CFR.385.2001(a)(2) (2013).
---------------------------------------------------------------------------

    On November 25, 2013, at 10:00 a.m. (Eastern Time), the Secretary
of the Commission, or her designee, will conduct a random drawing to
determine the filing priority of the applicants identified in this
notice. The Commission will select between the two competing permit
applications as provided in section 4.37 of its regulations.\2\ The
priority established by this drawing will be used to determine which
applicant, between those with identical filing times, will be
considered to have the first-filed application.
---------------------------------------------------------------------------

    \2\ See id. 4.37.
---------------------------------------------------------------------------

    The drawing is open to the public and will be held in room 2C, the
Commission Meeting Room, located at 888 First Street NE., Washington,
DC 20426. The Secretary will issue a subsequent notice announcing the
results of the drawing.

    Dated: November 19, 2013.
Nathaniel J. Davis, Sr.,
Deputy Secretary.
[FR Doc. 2013-28345 Filed 11-25-13; 8:45 am]
BILLING CODE 6717-01-P


[Federal Register Volume 88, Number 186 (Wednesday, September 27, 2023)]
[Notices]
[Pages 66479-66480]
[FR Doc No: 2023-21027]

-----------------------------------------------------------------------

DEPARTMENT OF HOMELAND SECURITY

Federal Emergency Management Agency

[Internal Agency Docket No. FEMA-4727-DR; Docket ID FEMA-2023-0001]

Mississippi; Major Disaster and Related Determinations

AGENCY: Federal Emergency Management Agency, DHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is a notice of the Presidential declaration of a major
disaster for the State of Mississippi (FEMA-4727-DR), dated August 12,
2023, and related determinations.

DATES: The declaration was issued August 12, 2023.

FOR FURTHER INFORMATION CONTACT: Dean Webster, Office of Response and
Recovery, Federal Emergency Management Agency, 500 C Street SW,
Washington, DC 20472,<PHONE_NUMBER>.

SUPPLEMENTARY INFORMATION: Notice is hereby given that, in a letter
dated August 12, 2023, the President issued a major disaster
declaration under the authority of the Robert T. Stafford Disaster
Relief and Emergency Assistance Act, 42 U.S.C. 5121 et seq. (the
``Stafford Act''), as follows:

    I have determined that the damage in certain areas of the State
of Mississippi resulting from severe storms, straight-line winds,
and tornadoes during the period of June 14 to June 19, 2023, is of
sufficient severity and magnitude to warrant a major disaster
declaration under the Robert T. Stafford Disaster Relief and
Emergency Assistance Act, 42 U.S.C. 5121 et seq. (the ``Stafford
Act''). Therefore, I declare that such a major disaster exists in
the State of Mississippi.
    In order to provide Federal assistance, you are hereby
authorized to allocate from funds available for these purposes such
amounts as you find necessary for Federal disaster assistance and
administrative expenses.
    You are authorized to provide Individual Assistance and Public
Assistance in the designated areas and Hazard Mitigation throughout
the State. Consistent with the requirement that Federal assistance
be supplemental, any Federal funds provided under the Stafford Act
for Public Assistance, Hazard Mitigation, and Other Needs Assistance
under section 408 will be limited to 75 percent of the total
eligible costs.

    Further, you are authorized to make changes to this declaration
for the approved assistance to the extent allowable under the
Stafford Act.

    The time period prescribed for the implementation of section
310(a), Priority to Certain Applications for Public Facility and Public
Housing Assistance, 42 U.S.C. 5153, shall be for a period not to exceed
six months after the date of this declaration.
    The Federal Emergency Management Agency (FEMA) hereby gives notice
that pursuant to the authority vested in the Administrator, under
Executive Order 12148, as amended, Darryl L. Dragoo, of FEMA is
appointed to act as the Federal Coordinating Officer for this major
disaster.
    The following areas of the State of Mississippi have been
designated as adversely affected by this major disaster:

    Jackson and Jasper Counties for Individual Assistance.
    Claiborne, Copiah, Covington, Jackson, Jasper, Jefferson,
Jefferson Davis, Lawrence, Leake, Neshoba, Newton, Rankin, Scott,
Simpson, Smith, and Wayne Counties and the Mississippi Band of
Choctaw Indians for Public Assistance.
    All areas within the State of Mississippi are eligible for
assistance under the Hazard Mitigation Grant Program.
    The following Catalog of Federal Domestic Assistance Numbers
(CFDA) are to be used for reporting and drawing funds: 97.030,
Community Disaster Loans; 97.031, Cora Brown Fund; 97.032, Crisis
Counseling; 97.033, Disaster Legal Services; 97.034, Disaster
Unemployment Assistance (DUA); 97.046, Fire Management Assistance
Grant; 97.048, Disaster Housing Assistance to Individuals and
Households In Presidentially Declared Disaster Areas; 97.049,
Presidentially Declared Disaster Assistance--Disaster Housing
Operations for Individuals and Households; 97.050, Presidentially
Declared Disaster Assistance to Individuals and Households--Other
Needs; 97.036, Disaster Grants--Public Assistance (Presidentially
Declared Disasters); 97.039, Hazard Mitigation Grant.

Deanne Criswell,
Administrator, Federal Emergency Management Agency.
[FR Doc. 2023-21027 Filed 9-26-23; 8:45 am]
BILLING CODE 9111-23-P


[Federal Register Volume 88, Number 63 (Monday, April 3, 2023)]
[Notices]
[Page 19635]
[FR Doc No: 2023-06855]

-----------------------------------------------------------------------

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. ER23-1470-000]

Cottontail Solar 2, LLC; Supplemental Notice That Initial Market-
Based Rate Filing Includes Request for Blanket Section 204
Authorization

    This is a supplemental notice in the above-referenced proceeding of
Cottontail Solar 2, LLC's application for market-based rate authority,
with an accompanying rate tariff, noting that such application includes
a request for blanket authorization, under 18 CFR part 34, of future
issuances of securities and assumptions of liability.
    Any person desiring to intervene or to protest should file with the
Federal Energy Regulatory Commission, 888 First Street NE, Washington,
DC 20426, in accordance with Rules 211 and 214 of the Commission's
Rules of Practice and Procedure (18 CFR 385.211 and 385.214). Anyone
filing a motion to intervene or protest must serve a copy of that
document on the Applicant.
    Notice is hereby given that the deadline for filing protests with
regard to the applicant's request for blanket authorization, under 18
CFR part 34, of future issuances of securities and assumptions of
liability, is April 17, 2023.
    The Commission encourages electronic submission of protests and
interventions in lieu of paper, using the FERC Online links at http://www.ferc.gov. To facilitate electronic service, persons with internet
access who will eFile a document and/or be listed as a contact for an
intervenor must create and validate an eRegistration account using the
eRegistration link. Select the eFiling link to log on and submit the
intervention or protests.
    Persons unable to file electronically may mail similar pleadings to
the Federal Energy Regulatory Commission, 888 First Street NE,
Washington, DC 20426. Hand delivered submissions in docketed
proceedings should be delivered to Health and Human Services, 12225
Wilkins Avenue, Rockville, Maryland 20852.
    In addition to publishing the full text of this document in the
Federal Register, the Commission provides all interested persons an
opportunity to view and/or print the contents of this document via the
internet through the Commission's Home Page (http://www.ferc.gov) using
the ``eLibrary'' link. Enter the docket number excluding the last three
digits in the docket number field to access the document. At this time,
the Commission has suspended access to the Commission's Public
Reference Room, due to the proclamation declaring a National Emergency
concerning the Novel Coronavirus Disease (COVID-19), issued by the
President on March 13, 2020. For assistance, contact the Federal Energy
Regulatory Commission at [email protected] or call toll-free,
(886) 208-3676 or TYY,<PHONE_NUMBER>.

    Dated: March 28, 2023.
Debbie-Anne A. Reese,
Deputy Secretary.
[FR Doc. 2023-06855 Filed 3-31-23; 8:45 am]
BILLING CODE 6717-01-P


[Federal Register Volume 85, Number 243 (Thursday, December 17, 2020)]
[Notices]
[Pages 81922-81923]
[FR Doc No: 2020-27801]

=======================================================================
-----------------------------------------------------------------------

ENVIRONMENTAL PROTECTION AGENCY

[EPA-HQ-OPP-2017-0440; FRL-10016-61-OMS]

Agency Information Collection Activities; Renewal Request
Submitted to OMB for Review and Approval; Comment Request; Plant
Incorporated Protectants; CBI Substantiation and Adverse Effects
Reporting (Renewal)

AGENCY: Environmental Protection Agency (EPA).

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Environmental Protection Agency (EPA) has submitted an
information collection request (ICR), Plant Incorporated Protectants;
CBI Substantiation and Adverse Effects Reporting (EPA ICR Number
1693.10, OMB Control Number 2070-0142) to the Office of Management and
Budget (OMB) for review and approval in accordance with the Paperwork
Reduction Act. This is a proposed extension of the ICR, which is
currently approved through February 28, 2021. Public comments were
previously requested via the Federal Register on August 17, 2020 during
a 60-day comment period. This notice allows for an additional 30 days
for public comments. A fuller description of the ICR is given below,
including its estimated burden and cost to the public. An agency may
not conduct or sponsor and a person is not required to respond to a
collection of information unless it displays a currently valid OMB
control number.

DATES: Additional comments may be submitted on or before January 19,
2021.

ADDRESSES: Submit your comments to EPA, referencing Docket ID No. EPA-
HQ-OPP-2017-0440, online using www.regulations.gov. EPA's policy is
that all comments received will be included in the public docket
without change including any personal information provided, unless the
comment includes profanity, threats, information claimed to be
Confidential Business Information (CBI), or other information whose
disclosure is restricted by statute.
    Submit written comments and recommendations to OMB for the proposed
information collection within 30 days of publication of this notice to
www.reginfo.gov/public/do/PRAMain. Find this particular information
collection by selecting ``Currently under 30-day Review--Open for
Public Comments'' or by using the search function.

FOR FURTHER INFORMATION CONTACT: Carolyn Siu, Mission Support Division
(7101M), Office of Program Support, Environmental Protection Agency,
1200 Pennsylvania Ave. NW, Washington, DC 20460-0001; telephone number:
(703) 347-0159; email address<EMAIL_ADDRESS>
SUPPLEMENTARY INFORMATION: Supporting documents, which explain in
detail the information that the EPA will be collecting, are available
in the public docket for this ICR. The docket can be viewed online at
www.regulations.gov or in person at the EPA Docket Center, WJC West,
Room 3334, 1301 Constitution Ave. NW, Washington, DC. The telephone
number for the Docket Center is<PHONE_NUMBER>. For additional
information about EPA's public docket, visit http://www.epa.gov/dockets.
    Abstract: EPA is responsible for the regulation of pesticides as
authorized by Federal Insecticide, Fungicide, and Rodenticide Act
(FIFRA). Prior to EPA granting a registration, the manufacturer of the
pesticide must demonstrate to the Agency that the use of the pesticide
product will not result in any unreasonable adverse effects to humans
or the environment. EPA is also responsible under the Federal Food,
Drug, and Cosmetic Act (FFDCA) for establishing a tolerance or
exemption from the requirement of a tolerance for pesticide residues on
food or feed.
    Form Numbers: None.
    Respondents/Affected entities: Pesticides and other agricultural
chemical manufacturing, research and development in the physical,
engineering, and life sciences, biological

products (except diagnostic) manufacturing, colleges, universities, and
professional schools, farm supplies wholesalers, flower, nursery stock,
and florists' supplies (wholesalers).
    Respondent's obligation to respond: Mandatory under FIFRA section 2
and applicable CBI requirements per 40 CFR part 2.
    Estimated number of respondents: 25 (total).
    Frequency of response: On occasion.
    Estimated total burden: 518 hours (per year). Burden is defined at
5 CFR 1320.03(b).
    Estimated total costs: $41,892 (per year), includes $0 annualized
capital or operation & maintenance costs.
    Changes in the estimates from the last approval: There are no
changes in the estimates.

Courtney Kerwin,
Director, Regulatory Support Division.
[FR Doc. 2020-27801 Filed 12-16-20; 8:45 am]
BILLING CODE 6560-50-P